Welcome to our dedicated page for Wellbeing Digital Sciences news (Ticker: KONEF), a resource for investors and traders seeking the latest updates and insights on Wellbeing Digital Sciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Wellbeing Digital Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Wellbeing Digital Sciences's position in the market.
Wellbeing Digital Sciences Inc. (OTC: KONEF) announced the issuance of 5,099,999 stock options and 3,000,000 restricted share units (RSUs) to its directors and employees as part of retention strategies. The options carry an exercise price of $0.215, vesting immediately for five years. Additionally, 2,975,000 options and 5,000,000 RSUs were canceled, voluntarily surrendered by holders. Wellbeing focuses on evidence-based healthcare solutions and aims to improve patient access to innovative treatments.
The latest clinical study on Beachbody's Shakeology® published in the
Wellbeing Digital Sciences Inc. (OTC: KONEF) announced the publication of a clinical study conducted by its subsidiary KGK Science for The Beachbody Company. The study investigated the effects of Shakeology®, a superfood nutrition shake, on weight loss and metabolic outcomes among 206 overweight adults over 12 weeks. Results indicated significant weight loss and improved metabolic markers in the Shakeology group compared to a placebo, supporting the product's claims. The findings contribute to the growing body of evidence for Shakeology's benefits in weight management and metabolic health.
Wellbeing Digital Sciences Inc. has engaged its wholly owned subsidiary, KGK Science Inc., to collaborate with Lophos Pharmaceuticals in evaluating market paths for sustainably grown, peyote-derived natural health products (NHPs). While peyote is legally cultivated in Canada, mescaline remains a controlled substance. The focus will include safety, quality requirements, and permissible claims for these products. Lophos aims to research responsible cultivation techniques to support sustainable supply.
Wellbeing Digital Sciences Inc. reported revenue of $1.66 million for the quarter ended January 31, 2022, a significant increase from $nil in the prior year. However, the company posted a net loss of $6.5 million, primarily driven by share-based payments and marketing expenses. Total assets decreased by 17% to $18.3 million. Notable achievements included the company's first IV ketamine treatment and the approval of its Reactivation therapy program by Veterans Affairs Canada. Najla Guthrie will take over as CEO on March 31, 2022.
Wellbeing Digital Sciences Inc. has announced the appointment of Najla Guthrie as the new CEO, effective March 31, 2022. Guthrie, currently the Chief Research Officer and President of KGK Science, will succeed Adam Deffett, who has been serving as Interim CEO since July 2021. Under Guthrie’s leadership, KGK has become a top contract research organization in North America. The company focuses on innovative clinical solutions and artificial intelligence-powered digital therapeutics, aiming to enhance mental health and wellness across the continent.
Wellbeing Digital Sciences has successfully conducted its first intravenous ketamine treatment in Ontario through a collaboration with Victoria Wellness and iHealthOX. This treatment, part of the Kite program, targets mental health conditions like anxiety and PTSD. The Victoria Wellness Centre is one of the few facilities in Canada offering this therapy, aiming to increase the number of patients treated. The company's innovative approach combines traditional treatment with digital tools, enhancing patient care and accessibility.
Wellbeing Digital Sciences Inc. (OTC: KONEF) provided a corporate update on its subsidiary KGK Science, which is operational in the psychedelics sector. In 2021, KGK secured contracts for 11 clinical trial projects and completed 9 trials, despite pandemic challenges. For 2022, KGK anticipates growth due to rising interest in psychedelics, managing 4 clinical trials including a Phase 1 psilocybin study. The company aims to enhance its network of clinics for trials and intends to launch a novel virtual trial platform in the coming year.
KetamineOne Capital Limited has partnered with Nova Mentis Life Science Corp. to develop psilocybin therapies for Fragile X Syndrome. They plan to submit a clinical trial application to Health Canada for a Phase 2A study evaluating psilocybin microdose therapy. Nova has achieved orphan drug designation in the US and EU for psilocybin, with successful preclinical studies on efficacy and safety. KGK Science’s expertise will aid in regulatory submissions and clinical trial management, aiming to meet significant unmet medical needs.
FAQ
What is the current stock price of Wellbeing Digital Sciences (KONEF)?
What is the market cap of Wellbeing Digital Sciences (KONEF)?
